This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Massarweh, S. Articles by Schiff, R. Search for Related Content PubMed PubMed Citation Articles by Massarweh, S. Articles by Schiff, R.

Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities

Authors' Affiliations: ¹ Department of Medicine and ² Markey Cancer Center, University of Kentucky, Lexington, Kentucky, ³ The Breast Center and ⁴ Department of Medicine, Baylor College of Medicine, One Baylor Plaza, BCM600, Houston, Texas

Requests for reprints: Suleiman Massarweh, Markey Cancer Center, 800 Rose Street, cc452, Lexington, KY 40536. Phone: 859-257-3608; Fax: 859-257-7715; E-mail: massarweh{at}uky.edu.

Abstract

Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor development and progression. ER-targeted therapy is therefore widely used in breast cancer to inhibit signaling through ER and disrupt breast cancer growth. This therapeutic strategy, particularly using the antiestrogen tamoxifen, is proven to increase the cure rates in early breast cancer, improve patient outcomes in advanced disease, and reduce breast cancer incidence in the prevention setting. Despite the recent integration of more powerful endocrine agents into breast cancer care, resistance to all forms of endocrine therapy remains a major problem. New insight into ER biology and progress in understanding resistance mechanisms, mediated by molecular crosstalk between ER and various growth factor signaling pathways, are generating tremendous promise for new therapeutic opportunities to target resistance and improve breast cancer disease outcomes.

This article has been cited by other articles:

				S. Pancholi, A. E Lykkesfeldt, C. Hilmi, S. Banerjee, A. Leary, S. Drury, S. Johnston, M. Dowsett, and L.-A. Martin ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2 Endocr. Relat. Cancer, December 1, 2008; 15(4): 985 - 1002. [Abstract] [Full Text] [PDF]

				M. Rokavec, W. Schroth, S. M.C. Amaral, P. Fritz, L. Antoniadou, D. Glavac, W. Simon, M. Schwab, M. Eichelbaum, and H. Brauch A Polymorphism in the TC21 Promoter Associates with an Unfavorable Tamoxifen Treatment Outcome in Breast Cancer Cancer Res., December 1, 2008; 68(23): 9799 - 9808. [Abstract] [Full Text] [PDF]

				S. John, I. Nayvelt, H.-C. Hsu, P. Yang, W. Liu, G. M. Das, T. Thomas, and T.J. Thomas Regulation of Estrogenic Effects by Beclin 1 in Breast Cancer Cells Cancer Res., October 1, 2008; 68(19): 7855 - 7863. [Abstract] [Full Text] [PDF]

				A. S. Kumar, C. C. Benz, V. Shim, C. A. Minami, D. H. Moore, and L. J. Esserman Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1028 - 1033. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Advances in Adjuvant Endocrine Therapy for Postmenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805. [Abstract] [Full Text] [PDF]